ENDV
Price:
$0.0007
Market Cap:
$223.13K
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concuss...[Read more]
Industry
Biotechnology
IPO Date
2012-11-15
Stock Exchange
PNK
Ticker
ENDV
According to Endonovo Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.07. This represents a change of -76.19% compared to the average of -0.29 of the last 4 quarters.
The mean historical PE Ratio of Endonovo Therapeutics, Inc. over the last ten years is -4872.66. The current -0.07 PE Ratio has changed -99.86% with respect to the historical average. Over the past ten years (40 quarters), ENDV's PE Ratio was at its highest in in the June 2017 quarter at 885.36. The PE Ratio was at its lowest in in the March 2015 quarter at -48581.73.
Average
-4872.66
Median
-0.63
Minimum
-39458.31
Maximum
0.35
Discovering the peaks and valleys of Endonovo Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.94%
Maximum Annual PE Ratio = 0.35
Minimum Annual Increase = -545.33%
Minimum Annual PE Ratio = -39458.31
Year | PE Ratio | Change |
---|---|---|
2023 | 0.35 | -545.33% |
2022 | -0.08 | -66.20% |
2021 | -0.23 | 90.40% |
2020 | -0.12 | 114.04% |
2019 | -0.06 | -94.48% |
2018 | -1.03 | -99.92% |
2017 | -1298.89 | 17.85% |
2016 | -1102.13 | -83.95% |
2015 | -6866.12 | -82.60% |
2014 | -39458.31 | 4.94% |
The current PE Ratio of Endonovo Therapeutics, Inc. (ENDV) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
0.01
5-year avg
-0.03
10-year avg
-4872.66
Endonovo Therapeutics, Inc.’s PE Ratio is greater than Bio-Path Holdings, Inc. (-0.24), less than Cingulate Inc. (-0.00), less than Purple Biotech Ltd. (-0.03), greater than Soleno Therapeutics, Inc. (-18.45), less than Genelux Corporation (0), greater than Comera Life Sciences Holdings, Inc. (-3.18), less than Dyadic International, Inc. (-0.00), greater than Monopar Therapeutics Inc. (-9.00), greater than Cellectis S.A. (-0.54), greater than Biotron Limited (-2.93), greater than Bioasis Technologies Inc. (-4.24), less than Covalon Technologies Ltd. (0), greater than Mosaic ImmunoEngineering Inc. (-111.00), greater than Quoin Pharmaceuticals, Ltd. (-23.07), greater than Bolt Biotherapeutics, Inc. (-0.33), greater than Pasithea Therapeutics Corp. (-0.34), less than MediciNova, Inc. (-0.00), less than Fresh Tracks Therapeutics, Inc. (-0.04), greater than null (-3.00),
Company | PE Ratio | Market cap |
---|---|---|
-0.24 | $3.53M | |
-0.00 | $15.16M | |
-0.03 | $4.36M | |
-18.45 | $2.49B | |
0 | $88.07M | |
-3.18 | $9.22K | |
-0.00 | $57.11M | |
-9.00 | $106.08M | |
-0.54 | $183.12M | |
-2.93 | $11.30M | |
-4.24 | $284.08K | |
0 | $72.60M | |
-111.00 | $7.24M | |
-23.07 | $2.95M | |
-0.33 | $22.14M | |
-0.34 | $3.93M | |
-0.00 | $104.47M | |
-0.04 | $4.30M | |
-3.00 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Endonovo Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Endonovo Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Endonovo Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Endonovo Therapeutics, Inc. (ENDV)?
What is the highest PE Ratio for Endonovo Therapeutics, Inc. (ENDV)?
What is the 3-year average PE Ratio for Endonovo Therapeutics, Inc. (ENDV)?
What is the 5-year average PE Ratio for Endonovo Therapeutics, Inc. (ENDV)?
How does the current PE Ratio for Endonovo Therapeutics, Inc. (ENDV) compare to its historical average?